Exosomes Secreted by the Cocultures of Normal and Oxygen-Glucose-Deprived Stem Cells Improve Post-stroke Outcome

Document Type

Article

Abstract

Emerging stroke literature suggests that treatment of experimentally induced stroke with stem cells offered post-stroke neuroprotection via exosomes produced by these cells. Treatment with exosomes has great potential to overcome the limitations associated with cell-based therapies. However, in our preliminary studies, we noticed that the exosomes released from human umbilical cord blood-derived mesenchymal stem cells (MSCs) under standard culture conditions did not improve the post-stroke neurological outcome. Because of this apparent discrepancy, we hypothesized that exosome characteristics vary with the conditions of their production. Specifically, we suggest that the exosomes produced from the cocultures of regular and oxygen-glucose-deprived (OGD) MSCs in vitro would represent the exosomes produced from MSCs that are exposed to ischemic brain cells in vivo, and offer similar therapeutic benefits that the cell treatment would provide. We tested the efficacy of therapy with exosomes secreted from human umbilical cord blood (HUCB)-derived MSCs under in vitro hypoxic conditions on post-stroke brain damage and neurological outcome in a rat model of transient focal cerebral ischemia. We performed the TTC staining procedure as well as the neurological tests including the modified neurological severity scores (mNSS), the modified adhesive removal (sticky-tape), and the beam walking tests before ischemia and at regular intervals until 7 days reperfusion. Treatment with exosomes obtained from the cocultures of normal and OGD-induced MSCs reduced the infarct size and ipsilateral hemisphere swelling, preserved the neurological function, and facilitated the recovery of stroke-induced rats. Based on the results, we conclude that the treatment with exosomes secreted from MSCs at appropriate experimental conditions attenuates the post-stroke brain damage and improves the neurological outcome.

Medical Subject Headings

Animals; Body Weight; Brain Damage, Chronic (etiology, pathology, prevention & control); Brain Ischemia (complications, therapy); Cell Hypoxia; Coculture Techniques; Exosomes; Fetal Blood (cytology); Glucose (pharmacology); Humans; Hypoxia-Inducible Factor 1, alpha Subunit (biosynthesis, genetics, physiology); Male; Mesenchymal Stem Cells (metabolism); Oxygen (pharmacology); Postural Balance; Psychomotor Performance; Rats; Reperfusion Injury (etiology, prevention & control); Up-Regulation

Publication Date

12-1-2019

Publication Title

Neuromolecular medicine

E-ISSN

1559-1174

Volume

21

Issue

4

First Page

529

Last Page

539

PubMed ID

31077035

Digital Object Identifier (DOI)

10.1007/s12017-019-08540-y

Link to Full Text

Share

COinS